rosiglitazone has been researched along with amg 221 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Bartberger, MD; Chen, MM; Cupples, R; Emery, MG; Fotsch, C; Gahm, K; Hague, A; Hale, C; Henriksson, MA; Hungate, RW; Johansson, L; Jona, J; Jordan, S; Joseph, S; Kim, KW; Komorowski, R; Li, V; Moniz, G; St Jean, DJ; Syed, R; Vallgårda, J; Véniant, MM; Wang, M; Williams, M; Zhang, J | 1 |
1 other study(ies) available for rosiglitazone and amg 221
| Article | Year |
|---|---|
Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Administration, Oral; Animals; Dogs; Drug Discovery; Enzyme Inhibitors; Humans; Male; Mice; Models, Molecular; Protein Conformation; Rats; Thiazoles | 2010 |